Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B2WK
|
||||
| Former ID |
DCL000275
|
||||
| Drug Name |
Ifetroban sodium
|
||||
| Synonyms |
Ifetroban sodium [USAN]; BMS-180291 sodium salt; BMS-180291-02
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10:I80-I82] | Phase 2 | [1] | ||
| Company |
Bristol-Myers Squibb
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H32N2O5
|
||||
| InChI |
InChI=1S/C25H32N2O5/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29)/t18-,20-,21+,23-/m0/s1
|
||||
| InChIKey |
BBPRUNPUJIUXSE-DXKRWKNPSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Thromboxane A2 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Platelet activation | |||||
| Reactome | Prostanoid ligand receptors | ||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| Thromboxane signalling through TP receptor | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Small Ligand GPCRs | |||||
| Signal amplification | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1987). | ||||
| REF 2 | AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.